Hematologic Malignancy
Mantle Cell Lymphoma
CI-CAN-00005962MCLExplore in graph →
Hematologic180 active trials5 approved drugs7 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00005962MCLExplore in graph →
Clinical trials
706 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (121)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07499128 | Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event | enrolling by invitation | N/A | 136 | National Cancer Institute (NCI)NIH | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07592481 | Connected Blood Pressure Monitoring in Patients With Hematologic Malignancies Initiating Covalent BTK Inhibitors(HEMO-CONNECT) | not yet recruiting | N/A | 40 | Centre Hospitalier de la côte BasqueOTHER | 0 | Jun 22, 2026 |
| clinicaltrials |
| NCT07476378 | A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell Malignancies(Archonc-001) | not yet recruiting | N/A | 69 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT04368702 | CONFIRM: Magnetic Resonance Guided Radiation Therapy(CONFIRM) | recruiting | N/A | 70 | Brigham and Women's HospitalOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT07257510 | Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma | recruiting | N/A | 34 | Peking University Third HospitalOTHER | 1 | Dec 2, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jun 25, 2026source: clinicaltrials